All In Biotech

Drug Trial Radar · NCT06681012

Gelsectan® in the Treatment of Patients With Diarrhoea-predominant Irritable Bowel Syndrome

Gelsectan® in the Treatment of Patients With Diarrhoea-predominant Irritable Bowel Syndrome: a Multicentre, Randomized, Double-blind, Parallel-group, Placebo-controlled Study

Last checked: Nov 20, 2026Latest source record: Apr 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 330 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

330

Planned (sponsor's estimate)

Start

Oct 22, 2024

Primary completion

Jul 2027

Study completion Jul 2027

Sponsor

Lead sponsor
Devintec SaglIndustry
Sponsor type
Industry
First posted
Nov 8, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Irritable Bowel Syndrome (IBS) is one of the major Disorders of Gut-Brain Interaction (DGBI) and the most frequent reasons for referral to both primary care providers and gastroenterologists.IBS is not a life-threatening disease, but imposes a significant burden on society, entailing a decrease in patients' Quality of Life (QoL), elevated rates of psychological comorbidities and loss of work productivity, which might be the greatest in subjects with IBS-D, for whom the fear of incontinence in a social situation can be especially debilitating. Moreover, IBS is associated with significant direct and indirect healthcare costs and has a considerable socioeconomic impact on society. Treatment strategy for IBS is usually based on predominant symptoms and their severity, and requires a strong patient-physician relationship, as well as both non-pharmacological and pharmacological approaches. Lifestyle interventions, such as dietary modifications, physical activity and lifestyle adjustments, and stress reduction/psychological therapy represent the most important initial non-pharmacological clinical approach for IBS patients, especially for those with mild disease. First-line pharmacological options for IBS-D include antidiarrheals, mainly loperamide, to control diarrhoea, as well as antispasmodic drugs to relieve IBS symptoms, in particular abdominal pain. Second-line therapies indicated for the treatment of global IBS-D symptoms include rifaximin, 5-Hydroxytryptamine (5-HT)3 receptor antagonists (alosetron, ondansetron and ramosetron) and eluxadoline. Other treatments recommended in patients with IBS-D consist of Tricyclic Anti-Depressants (TCAs) and bile acid sequestrants. Notably, management of patients with IBS is challenging since diagnosis and treatment could require several therapeutical strategies with often partial and unsatisfactory results. Indeed, most patients with IBS are dissatisfied with their current therapy and 34% report no symptom control, according to the IBS Global Impact Report of 2018. At present, there is a growing interest in therapeutic approaches for IBS-D aimed at improving intestinal barrier integrity for a more efficient control of symptoms, considering that an intestinal epithelial barrier dysfunction and mucosal immune activation have been suggested as a central mechanism in IBS-D pathophysiology. In this perspective, film-forming agents capable of protecting the intestinal mucosal barrier, such as Xyloglucan (XG) and Pea protein may represent a valid alternative therapeutic option for the management of IBS-D. Gelsectan® is a CE-marked medical device under the European Union (EU) Medical Device Regulation (MDR) 2017/745, whose classification under the MDR is class III. Gelsectan® contains XG, Pea protein, grape seed extract, and Xylo-Oligosaccharides (XOS) and is indicated for symptomatic relief and prevention of chronic or relapsing diarrhoea, abdominal tension, pain, bloating and flatulence, as well as protection and restoration of intestinal mucosal function. Based on previous non-clinical studies and two clinical investigations, Gelsectan® seems to be safe and exert a protective action on the intestinal mucosa, mediating the restoration of intestinal permeability and the improvement of gastrointestinal symptoms associated with IBS-D. In particular, a 28-day treatment with Gelsectan® significantly reduced IBS-D-associated diarrhoea, abdominal pain and bloating, with no related adverse events in a randomized, placebo-controlled, cross-over clinical study. Moreover, Gelsectan® treatment for 6 months was generally safe and effective in improving IBS severity, diarrhoea and bowel habit, as well as pain and bloating, in a recent multicentre, open-label, prospective, observational study. Of note, Gelsectan® was also mentioned in the recent clinical practice guidelines on IBS-D and functional diarrhoea of the United European Gastroenterology (UEG) and the European Society for Neurogastroenterology and Motility (ESNM), and a recent consensus on IBS conducted by a panel of Belgian gastroenterologists. With these premises, the present study aims to further assess the performance and safety of Gelsectan® within the scope of its intended purpose, compared with placebo, on overall abdominal pain and symptoms in patients with IBS-D in a randomized, double-blind, parallel-group clinical study.

Conditions

  • Irritable Bowel Syndrome (IBS)
  • Irritable Bowel Syndrome of Diarrhea Type (IBS-D)

Interventions

  • Gelsectan®Device

    Oral capsules are to be taken twice a day for 2 months (two capsules in the morning before breakfast and two capsules in the evening before dinner during the first 4 weeks of treatment; one capsule in the morning and one in the evening during the following 4 weeks of treatment).

  • PlaceboDrug

    Oral capsules are to be taken twice a day for 2 months (two capsules in the morning before breakfast and two capsules in the evening before dinner during the first 4 weeks of treatment; one capsule in the morning and one in the evening during the following 4 weeks of treatment).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Effect of Gelsectan® on the composite response rate for abdominal pain and stool consistency over the 8-week treatment period, at the end of treatment, in patients with IBS-D, according to Rome IV criteria.Time frame: From enrollment to the end of treatment at 8 weeks

Locations

12 sites in 4 countries. Site status is shown where the registry gives one.

  • University Hospitals Leuven (UZ Leuven)

    Leuven, Belgium · Recruiting

  • Hôpital Avicenne

    Bobigny, France · Recruiting

  • CHU de Rouen

    Rouen, France · Recruiting

  • IRCCS Ca' Granda Ospedale Maggiore Policlinico Foundation

    Milan, Italy · Recruiting

  • AOU Federico II di Napoli

    Naples, Italy · Recruiting

  • Azienda Ospedale Università Padova

    Padova, Italy · Recruiting

  • Fondazione IRCCS Policlinico San Matteo

    Pavia, Italy · Recruiting

  • Azienda Ospedaliero Universitaria Pisana (AOUP)

    Pisa, Italy · Recruiting

  • S. Andrea University Hospital

    Roma, Italy · Recruiting

  • IRCCS Azienda Ospedaliero Universitaria di Bologna Policlinico Sant'Orsola

    Bologna, BO, Italy · Recruiting

  • Hospital Universitario Vall d´Hebron

    Barcelona, Spain · Recruiting

  • Hospital Universitario Ramón y Cajal

    Madrid, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.